VivaVision Biotech Welcomes Leading Ophthalmology Expert

Author: Dominic Sanders Updated: 08-12-2025 12:12 PM

VivaVision Biotech Strengthens Advisory Board with Expert

Recently, VivaVision Biotech Co., Ltd. (VivaVision) proudly announced the addition of Dr. Quan Dong Nguyen, a globally recognized figure in the field of ophthalmology, to its Scientific Advisory Board. This strategic appointment marks a significant step forward for the company as it furthers its commitment to innovative eye care solutions.

Meet Dr. Quan Dong Nguyen

Dr. Quan Dong Nguyen is currently affiliated with the Byers Eye Institute at Stanford University, where he serves as a professor of ophthalmology and has further appointments in medicine and pediatrics. His research primarily revolves around clinical trials for macular edema, neovascular age-related macular degeneration (AMD), and various ocular inflammatory diseases. Having pioneered evaluations of drugs like aflibercept and ranibizumab, Dr. Nguyen's contributions are foundational in establishing effective treatment protocols for retinal problems.

Impact on VivaVision's Projects

Dr. Nguyen's expertise is expected to significantly enhance VivaVision's research and development initiatives. He expressed enthusiasm about joining the team and highlighted the potential of VivaVision's dual JAK1/TYK2 inhibitors, VVN461 and VVN481, developed for treating ocular inflammatory conditions. These innovative therapies aim to provide patients with safer alternatives to current corticosteroid treatments.

Comments from Leadership

Wang Shen, the Founder and CEO of VivaVision Biotech, expressed honor at having Dr. Nguyen join the advisory board. He emphasized that Dr. Nguyen’s extensive knowledge in managing conditions such as diabetic macular edema and inflammatory diseases will be invaluable as VivaVision continues to expand its research endeavors.

About VivaVision

Established in 2016, VivaVision Biotech focuses on pioneering clinical therapies for ocular diseases. With a commitment to addressing unmet medical needs, the company is advancing leading-edge treatments, including:

Innovative Pipeline Developments

1. VVN461: A dual JAK1/TYK2 immunomodulator designed to manage post-operative inflammation and non-infectious anterior uveitis.

2. VVN001: An investigational remedy for dry eye disease.

3. VVN1901: Targeted treatment for neurotrophic keratitis.

4. VVN481: A non-steroidal treatment for posterior uveitis and related inflammatory conditions.

In addition, VivaVision is dedicated to discovering groundbreaking therapies that tackle both anterior and posterior ocular diseases, effectively addressing the challenges faced by patients worldwide.

Frequently Asked Questions

What is the significance of Dr. Quan Dong Nguyen's appointment?

Dr. Nguyen's experience in clinical trials and ocular diseases strengthens VivaVision's advisory board, enhancing its research capabilities.

What are VVN461 and VVN481?

These are dual JAK1/TYK2 inhibitors aimed at treating ocular inflammatory diseases and offer new options for patients.

When was VivaVision Biotech founded?

VivaVision Biotech was founded in 2016 with a focus on developing innovative therapies for eye diseases.

What conditions does VivaVision's pipeline aim to treat?

VivaVision's pipeline focuses on various ocular diseases, including dry eye disease, inflammation, and retinal disorders.

How does VivaVision approach research and development?

The company emphasizes innovative strategies to address unmet patient needs in ocular health through advanced therapies.

About The Author

Dominic Sanders here, a writer and financial specialist committed to helping my readers understand the world of finance. Having a strong financial background and a lot of experience, I concentrate on using my blog posts and articles to translate difficult financial subjects into understandable, doable advice. My goal in writing is to arm you with the information and skills need to make wise financial choices.

Writing for several financial blogs has let me interact with a wide range of readers, from novice investors seeking new perspectives to seasoned investors. My mission is to make money understandable and approachable so you may confidently take charge of your financial future. I appreciate you walking this road with me to success and financial literacy.

Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.